IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4434
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$239M
Miguel Martin
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; herb mills for using CanniMed herbal cannabis products.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ACB AURORA CANNABIS INC | 31 | 29 | 22 | 22 | - | - | 1.1% | 0.8% | - | - | - | - | 0.0% | 26.0x | $239M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
AURORA CANNABIS INC (ACB) receives a "Avoid" rating with a composite score of 31.3/100. It ranks #4434 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ACB.
View All RatingsROIC -720.4% vs WACC 7.9% (spread -728.3%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover 0.00x
Rev growth N/A, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate AURORA CANNABIS INC (ACB) as Avoid with a composite score of 31.3/100 at a current price of $3.79. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
AURORA CANNABIS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.3/100 places it at rank #4434 in our full universe.
No Moat
Medium
Standard
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
AURORA CANNABIS INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags AURORA CANNABIS INC with an Avoid rating, assigning a composite score of 31.3/100 and 1 out of 5 stars. Ranked #4434 of 7,333 stocks, ACB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ACB's quality score of 29/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 1.1% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
ACB registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.54x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 57/100, ACB exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of 0.8% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
AURORA CANNABIS INC is experiencing notably weak momentum with a score of just 22/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.18 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
ACB's stability score of 43/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.18 and a debt-to-equity ratio of 26.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
AURORA CANNABIS INC's short interest score of 28/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 26.00x), micro-cap liquidity risk. At $239M (micro-cap), ACB carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
AURORA CANNABIS INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4434 of 7,333 overall (40th percentile). Key comparisons include ROE of 1.1% exceeding the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ACB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (22) would have the largest impact on the composite score.
ROE 159% BELOW SECTOR MEDIAN
Debt/Equity 12281% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.
Quantum computing company Rigetti Computing experienced a significant stock decline in November 2025, with Q3 revenues falling 18% and net losses expanding to $201 million, reflecting ongoing challenges in the emerging quantum computing market.
A video posted on Truth Social by the Commonwealth Project suggests potential federal marijuana legalization, with implications for Medicare coverage of medical marijuana and significant stock market reactions in cannabis companies.
Cannabis Concentrate Market Surge in Concentrates Fueled by 15.7% CAGR, Potency Precision, and the Transition from Traditional Flower to High-End Extracts NEWARK, DE / ACCESS Newswire / February 20, 2026 / The global cannabis sector is undergoing ...
Key opportunities in the cannabidiol market include growth from increasing medical cannabis legalization, rising alternative medicine usage, expanding hemp cultivation, and CBD's integration into healthcare. Growth drivers also include demand for plant-based therapeutics and innovations in epilepsy treatments. Cannabidiol Market Cannabidiol Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Cannabidiol Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cannabi